AR047764A1 - Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad - Google Patents
Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidadInfo
- Publication number
- AR047764A1 AR047764A1 ARP040103811A ARP040103811A AR047764A1 AR 047764 A1 AR047764 A1 AR 047764A1 AR P040103811 A ARP040103811 A AR P040103811A AR P040103811 A ARP040103811 A AR P040103811A AR 047764 A1 AR047764 A1 AR 047764A1
- Authority
- AR
- Argentina
- Prior art keywords
- dislipidemies
- obesity
- prevention
- preparation
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Utilizacion de un conjunto antagonista de los receptores de cannabinoides CB1, derivados de pirazol, solo o asociado con otro principio activo, para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad, tales como el síndrome metabolico, los riesgos cardiovasculares y las enfermedades hepáticas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0312553A FR2861300B1 (fr) | 2003-10-24 | 2003-10-24 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
FR0314763A FR2861301B1 (fr) | 2003-10-24 | 2003-12-15 | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
FR0401193A FR2861302A1 (fr) | 2003-10-24 | 2004-02-05 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
FR0403252A FR2861303A1 (fr) | 2003-10-24 | 2004-03-26 | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047764A1 true AR047764A1 (es) | 2006-02-22 |
Family
ID=34426973
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103811A AR047764A1 (es) | 2003-10-24 | 2004-10-21 | Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad |
ARP070104905A AR063551A2 (es) | 2003-10-24 | 2007-11-05 | Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y el tratamiento de las disciplinas y de las enfermedades asociadas a las dislipidemias y/o a la obesidad |
ARP070104904A AR063550A2 (es) | 2003-10-24 | 2007-11-05 | Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104905A AR063551A2 (es) | 2003-10-24 | 2007-11-05 | Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y el tratamiento de las disciplinas y de las enfermedades asociadas a las dislipidemias y/o a la obesidad |
ARP070104904A AR063550A2 (es) | 2003-10-24 | 2007-11-05 | Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad |
Country Status (18)
Country | Link |
---|---|
US (2) | US20070072907A1 (es) |
EP (1) | EP1680117A2 (es) |
JP (1) | JP2007509113A (es) |
KR (1) | KR20060100443A (es) |
AR (3) | AR047764A1 (es) |
AU (1) | AU2004289078A1 (es) |
BR (1) | BRPI0415538A (es) |
CA (1) | CA2543582A1 (es) |
FR (1) | FR2861303A1 (es) |
IL (1) | IL175103A0 (es) |
MA (1) | MA28105A1 (es) |
ME (1) | MEP10608A (es) |
NZ (1) | NZ547375A (es) |
RS (1) | RS20060344A (es) |
RU (1) | RU2357731C2 (es) |
SG (1) | SG149078A1 (es) |
TW (1) | TWI286935B (es) |
WO (1) | WO2005046689A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
EP1745782A1 (en) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome |
ES2326857B1 (es) * | 2005-07-15 | 2010-05-11 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidicos del sindrome metabolico. |
WO2007009698A1 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Combination of pyrazoline type cannabinoid receptor antagonist and statin |
ES2325722B1 (es) * | 2005-07-15 | 2010-04-19 | Laboratorios Del Dr.Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para la preparacion de medicamentos para el tratamiento del sindrome metabolico. |
EP1745781A1 (en) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Combination of pyrazoline type cannabinoid receptor antagonist and statin |
EP1946779A1 (en) * | 2007-01-16 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Combination of substituted pyrazolines and agent for treating dyslipidemia |
EP1985295A1 (en) | 2007-04-04 | 2008-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders |
KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
ES2349838B1 (es) * | 2009-05-04 | 2011-11-15 | Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im | Derivados de pirazol bivalentes como inhibidores de ingesta |
RU2568896C2 (ru) * | 2013-07-31 | 2015-11-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Лекарственное средство на основе вещества, влияющего на эндоканнабиноидную систему |
WO2018064654A1 (en) * | 2016-10-01 | 2018-04-05 | James Smeeding | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
FR2799124B1 (fr) * | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
HUP0401567A3 (en) * | 2001-09-21 | 2005-06-28 | Solvay Pharm Bv | Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them |
US6864268B2 (en) * | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
DE60334787D1 (de) * | 2002-03-12 | 2010-12-16 | Merck Sharp & Dohme | Substituierte amide |
WO2003087037A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
KR101120337B1 (ko) * | 2002-07-09 | 2012-02-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법 |
US20050288213A1 (en) * | 2002-07-18 | 2005-12-29 | Macneil Douglas J | Combination therapy for the treatment of obesity |
AU2003257145B2 (en) * | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
US20050101542A1 (en) * | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
US20070099884A1 (en) * | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
EP1635813A4 (en) * | 2003-06-06 | 2009-07-01 | Merck & Co Inc | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA |
WO2004110368A2 (en) * | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of hypertension |
RU2006110545A (ru) * | 2003-09-02 | 2007-10-10 | Зольвай Фармасьютикалз Гмбх (De) | Новое медицинское применение избирательных антагонистов св1-рецептора |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
EP1680116A1 (en) * | 2003-10-24 | 2006-07-19 | Solvay Pharmaceuticals GmbH | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
WO2005094305A2 (en) * | 2004-03-31 | 2005-10-13 | Neurogen Corporation | Combination therapy for weight management |
US20050281868A1 (en) * | 2004-06-21 | 2005-12-22 | Fairfield Clinical Trials, Llc | Transdermal delivery system for statin combination therapy |
-
2004
- 2004-03-26 FR FR0403252A patent/FR2861303A1/fr not_active Withdrawn
- 2004-10-21 AR ARP040103811A patent/AR047764A1/es not_active Application Discontinuation
- 2004-10-22 CA CA002543582A patent/CA2543582A1/fr not_active Abandoned
- 2004-10-22 NZ NZ547375A patent/NZ547375A/en unknown
- 2004-10-22 AU AU2004289078A patent/AU2004289078A1/en not_active Abandoned
- 2004-10-22 RU RU2006117790/15A patent/RU2357731C2/ru not_active IP Right Cessation
- 2004-10-22 TW TW093132275A patent/TWI286935B/zh not_active IP Right Cessation
- 2004-10-22 WO PCT/FR2004/002715 patent/WO2005046689A2/fr active Application Filing
- 2004-10-22 ME MEP-106/08A patent/MEP10608A/xx unknown
- 2004-10-22 KR KR1020067009975A patent/KR20060100443A/ko not_active Application Discontinuation
- 2004-10-22 EP EP04805278A patent/EP1680117A2/fr not_active Withdrawn
- 2004-10-22 JP JP2006536128A patent/JP2007509113A/ja not_active Withdrawn
- 2004-10-22 BR BRPI0415538-6A patent/BRPI0415538A/pt not_active IP Right Cessation
- 2004-10-22 RS YUP-2006/0344A patent/RS20060344A/sr unknown
- 2004-10-22 SG SG200809686-9A patent/SG149078A1/en unknown
-
2006
- 2006-04-23 IL IL175103A patent/IL175103A0/en unknown
- 2006-04-24 MA MA28959A patent/MA28105A1/fr unknown
- 2006-04-24 US US11/410,226 patent/US20070072907A1/en not_active Abandoned
-
2007
- 2007-11-05 AR ARP070104905A patent/AR063551A2/es unknown
- 2007-11-05 AR ARP070104904A patent/AR063550A2/es unknown
-
2009
- 2009-05-11 US US12/463,652 patent/US20090215755A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MEP10608A (en) | 2010-06-10 |
KR20060100443A (ko) | 2006-09-20 |
MA28105A1 (fr) | 2006-08-01 |
US20090215755A1 (en) | 2009-08-27 |
AR063550A2 (es) | 2009-01-28 |
RS20060344A (en) | 2008-08-07 |
WO2005046689A2 (fr) | 2005-05-26 |
AR063551A2 (es) | 2009-01-28 |
JP2007509113A (ja) | 2007-04-12 |
US20070072907A1 (en) | 2007-03-29 |
IL175103A0 (en) | 2008-04-13 |
AU2004289078A1 (en) | 2005-05-26 |
TWI286935B (en) | 2007-09-21 |
EP1680117A2 (fr) | 2006-07-19 |
BRPI0415538A (pt) | 2006-12-26 |
RU2006117790A (ru) | 2007-12-10 |
CA2543582A1 (fr) | 2005-05-26 |
RU2357731C2 (ru) | 2009-06-10 |
SG149078A1 (en) | 2009-01-29 |
WO2005046689A3 (fr) | 2005-10-13 |
FR2861303A1 (fr) | 2005-04-29 |
NZ547375A (en) | 2009-10-30 |
TW200526216A (en) | 2005-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063551A2 (es) | Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y el tratamiento de las disciplinas y de las enfermedades asociadas a las dislipidemias y/o a la obesidad | |
NO20076109L (no) | Substituerte arylpyrazoler, og anvendelser som parasitticidale midler | |
MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
EA200700653A1 (ru) | Система контролируемой доставки | |
ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
ECSP088852A (es) | Azolopirimidinas como inhibidores de la actividad canabinoidea 1 | |
MX2007012212A (es) | 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa. | |
TN2011000172A1 (en) | Therapeutic antiviral peptides | |
ECSP067054A (es) | Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos | |
CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
GT200500179BA (es) | Mezclas sinergistas de agentes de antranilamida para el control de plagas de invertebrados | |
ECSP10010439A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
MX2010001574A (es) | Ligandos del receptor cannabinoide. | |
MX2009006567A (es) | Pirimidinilpirazoles como principios activos insecticidas y parasiticidas. | |
CL2008002242A1 (es) | Compuestos derivados de n-cicloalquil-n-carboxamida, tiocarboxamida, biciclicas o derivados de carboximidamida n-sustituida; composicion fungicida; y metodo para controlar los hongos fitopatogenos de los cultivos. | |
NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren | |
BRPI0518299A2 (pt) | ciclopentanonas 2,3,4-substituÍdas como agentes terapÊuticos | |
EA201070689A1 (ru) | Композиция для личного ухода | |
WO2007009701A3 (en) | Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome | |
WO2008008700A3 (en) | Substituted cyclopentane derivatives as therapeutic agents | |
BRPI0716643A2 (pt) | amidas terapêuticas e compostos relacionados | |
EA200900942A1 (ru) | Гербицидная композиция | |
DK1893237T3 (da) | Farmaceutisk sammensætning, der omfatter en organopolysiloxan ela-stomer og et solubiliseret aktivt stof | |
CR11340A (es) | Mezclas fungicidas de triticonazol y difenoconazol | |
DOP2004001017A (es) | Utilizacion de un derivado de pirazol para la preparacion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |